ALLMedicine™ Paronychia Center
Research & Reviews 161 results
International Journal of Dermatology; Gupta MK, Lipner SR
Jul 10th, 2021 - Chemotherapy-associated paronychia (CAP) is an inflammation of the nail folds in response to various chemotherapeutic medications. Altered proliferation of keratinocytes or nail matrix stem cells is thought to be a major causative factor. Prophyla...
Orthopaedics & Traumatology, Surgery & Research : OTSR; Matter-Parrat V, Lazarus P et. al.
Jun 9th, 2021 - There is no consensus in the literature, or even within the same team, on the most appropriate treatment option for acute paronychia with abscess formation. The performance of an evaluation of professional practices (EPP) using a clinical audit me...
Dermatologic Therapy; Filoni A, Ambrogio F et. al.
Jun 3rd, 2021 - An increasing use of beta-blockers in dermatology has been described over the last 10 years, despite the fact that their use in diseases other than infantile hemangiomas is off-label. This review discusses the emerging role of topical beta-blocker...
Dermatologic Surgery : Official Publication for American ... Hanania HL, Pacha O et. al.
May 25th, 2021 - Paronychia is a common toxicity associated with targeted anticancer therapies. Antibiotics and steroids are the standard treatments for severe paronychia, yet they are often inadequate, prolonging the patient's suffering and resulting in changes t...
The Journal of Dermatological Treatment; Jornsamer C, Theerawattanawit C et. al.
May 8th, 2021 - We evaluated the efficacy and safety of red light LED as an adjuvant treatment for epidermal growth factor receptor inhibitor-induced paronychia. Eight patients were recruited in this randomized, single-blinded controlled trial. They were randomiz...
Guidelines 1 results
Drugs Califano R, Tariq N et. al.
Jul 19th, 2015 - Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). These drugs have a prove...
Drugs 2 results see all →
Clinicaltrials.gov 2 results
Jan 25th, 2019 - Paronychia is inflammation of the skin surrounding the nail that leads to secondary infection. Iatrogenic paronychia has been clearly associated with cancer chemotherapies. This phase-2 trial is a dose finding study and will evaluate topical VBP-9...
Jan 2nd, 2017 - Method: Participants with ingrown toenail and >= 12 years old with total 40 ingrown toenails were included. Investigators divide patients to 3 group: (1) combiped group: Participants with non-infected or mild infected ingrown nail, combiped nail b...
News 24 results
Apr 13th, 2020 - The Food and Drug Administration has approved selumetinib for the treatment of pediatric patients aged 2 years and older with type 1 neurofibromatosis (NF1) with symptomatic, inoperable plexiform neurofibromas. FDA approval was based on results fr...
Josh A. Hammel, MD, Dean Elhag, MD et. al.
Jan 27th, 2020 - To the Editor: The epidermal growth factor receptor (EGFR) signaling pathway plays a role in the differentiation, proliferation, and survival of several cell types. 1 Erlotinib is an EGFR inhibitor that targets aberrant cells that overexpress this.
MDedge Family Medicine;
Aug 22nd, 2019 - The patient was given a diagnosis of green nail syndrome (GNS), an infection of the nail bed caused by Pseudomonas aeruginosa. These bacteria produce pyocyanin, a blue-green pigment that discolors the nail.
Oncology Practice; Sharon Worcester
Sep 28th, 2018 - The Food and Drug Administration has approved dacomitinib tablets (VIZIMPRO) for the first-line treatment of metastatic non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitut.
Dec 28th, 2017 - Action Points Dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib (Tykerb) and trastuzumab (Herceptin) + an aromatase inhibitor (AI) improved progression-free survival (PFS) versus single HER2 blockade in HER2-positive/hor...